Alexza's Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference
The presentation will be webcast from the Waldorf-Astoria Hotel in NewYork. To access the live presentation via the Web, please go to the InvestorRelations tab at http://www.alexza.com or athttp://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=ALXA&item_id=1752205.A replay of the Webcast will be made available approximately 24 hours afterthe live presentation and the replay will be archived for 14 days.
Alexza is a biopharmaceutical company focused on the development andcommercialization of novel, proprietary products for the treatment of acuteand intermittent conditions. The Company's technology, the Staccato(R)system, vaporizes unformulated drug to form a condensation aerosol that allowsrapid systemic drug delivery through deep lung inhalation. The drug isquickly absorbed through the lungs into the bloodstream, providing speed oftherapeutic onset that is comparable to intravenous administration, but withgreater ease, patient comfort and convenience. Alexza has six productcandidates in development; AZ-004 (Staccato loxapine) for the treatment ofacute agitation in schizophrenic and bipolar disorder patients, AZ-001(Staccato prochlorperazine) for the acute treatment of migraine headaches,AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches,AZ-002 (Staccato alprazolam) for the acute treatment of panic attacksassociated with panic disorder, AZ-003 (Staccato fentanyl) for the treatmentof breakthrough pain in cancer and non-cancer patients, and AZ-007 (Staccatozaleplon) for the treatment of insomnia. More information, including this andpast press releases from Alexza is available online at http://www.alexza.com.
Safe Harbor Statement
The anticipated presentation will contain forward-looking statements thatinvolve significant risks and uncertainties. Any statement describing theCompany's expectations or beliefs is a forward-looking statement, as definedin the Private Securities Litigation Reform Act of 1995, and should beconsidered an at-risk statement. Such statements are subject to certain risksand uncertainties, particularly those inherent in the process of developingand commercializing drugs. The Company's forward-looking statements alsoinvolve assumptions that, if they prove incorrect, would cause its results todiffer materially from those expressed or implied by such forward-lookingstatements. These and other risks concerning Alexza's business are describedin additional detail in the Company's Annual Report on Form 10-K/A for theyear ended December 31, 2006, and the Company's other Periodic and CurrentReports filed with the Securities and Exchange Commission. Forward-lookingstatements contained in this announcement are made as of this date, and weundertake no obligation to publicly update any forward-looking statement,whether as a result of new information, future events or otherwise.
SOURCE Alexza Pharmaceuticals, Inc.
You May Also Like